ASCO: Radiation therapy in one dose
Results from the TARGIT-A trialJune 7, 2010
Some women with early breast cancer may be able to get by with a single dose of radiation therapy at the time of surgery, rather than daily radiation over several weeks, according to results from a prospective, randomized, Phase III trial, known as the TARGIT-A trial, published online in the Lancet. The results were also presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. However, patients have only been followed for four years, so it is possible that with longer follow-up the single dose will prove to be less effective.
Over 2000 women with invasive ductal carcinoma who were undergoing breast-conserving surgery were randomized to receive either targeted, single-dose radiotherapy during surgery, or whole breast external beam radiotherapy over several weeks. After 4 years, the recurrence rate was similar in both groups. There were six local recurrences in the single dose radiotherapy group and five in the external beam radiotherapy group. The frequency of any complications and major toxicity was similar in the two groups, however, radiotherapy toxicity was lower in the targeted single dose radiotherapy group (six patients) than in the external beam radiotherapy group (23 patients).
MYTHS VS. TRUTHS
Brush up on your breast cancer myths and truths. Find out if you know more about breast cancer than the American public.
I'll Talk
Speak up and out about breast cancer. Say, "I'll Talk" and commit to a conversation about breast cancer with people you know and care about.
Understanding Research and Evidence
Comments
Tina
Date: May 7, 2012Nike Shox
Date: May 16, 2012